CAACB publications summarize best practices and learnings to mitigate the risk of adventitious agent contamination in biomanufacturing.
- Su, J., Rice, J., Hoffman, J., Alvarado, S., Bailey, M., Kopp, M., Murphy, M., Kiss, R., Barone, P.W., Wiebe, M.E., Springs, S.L., Dehghani, H., Chen, D. Revisiting mouse minute virus inactivation by high temperature short time treatment. Biotechnology & Bioengineering, April 29, 2021
- PW Barone, et. al. The Impact of SARS-CoV-2 on Biomanufacturing Operations. BioPharm International 33 (8) 2020.
- PW Barone, ME Wiebe, JC Leung, et al. Viral contamination in biologic manufacture and implications for emerging therapies. Nat Biotechnol. 38, 563–572 (2020)
- PW Barone, et. al. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing. PDA J. Pharm. Sci. Tech. March 2019, 73 (2) 191-203
- PW Barone, FJ Keumurian, J Leung, SL Springs, R Domike, GK Raju, S Monpoeho, K Murray, S Reich, M Ruffing, and M Wiebe. “Quality Risk Management in the Context of Viral Contamination”. In Microbial Control and Identification, edited by Donna Reber (PDA, Washington, 2018)